用多分子标记物预测新辅助化疗疗效

doi:10.3971/j.issn.1000-8578.2039

用多分子标记物预测新辅助化疗疗效

Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients by Using Molecular Markers

摘要

摘要: 目的探讨ER、PR、C-erbB-2和P53与乳腺癌新辅助化疗疗效的相关性。方法局部晚期乳腺癌患者接受EC或TP方案化疗，化疗前空芯针穿刺活检，采用免疫组化法检测肿瘤组织的ER、PR、C-erbB-2和P53的表达情况。结果22例新辅助化疗RR达81．8％，其中CR5例（22．7％），pCR4例（18．2％），PR13例（59．1%），SD4例（18．2％）。研究发现ER、PR和C-erbB-2表达在3组间有显著性差异，但与新辅助化疗的疗效无关联性。结论ER、PR和C-erbB-2的表达在不同疗效组有差异，但目前不能预测新辅助化疗的疗效。

Abstract: Objective 　To investigate the expression and correlation of ER、PR、C2erbB22 and P53 with the response of neoadjuvant chemotherapy. Methods 　The local advanced breast cancer patient s were under2 went core needle biop sy before they were given neoadjuvant chemotherapy of EC or TP. Expression of ER、PR、C2erbB22 and P53 were tested in 22 cases by immunohistochemical methods. Results 　The re2 sponse rate was 81. 8 %, including CR 22. 7 % and PR 59. 1 %, and the SD is 18. 2 %。There was a statit2 ical significance between expression of ER、PR 、C2erbB22 and the response to neoadjuvant chemotherapy. But there was no correlation between expression of ER、PR 、C2erbB22 and the response to neoadjuvant chemotherapy. Conclusion 　There is a significant difference between expression of ER、PR 、C2erbB22 and the response to neoadjuvant chemotherapy, but we can't predict the response of neoadjuvant chemothera2 py. We need to do more research to separtate the CR and SD.

HTML全文

参考文献(0)

施引文献

资源附件(0)